Is a skin test required before administering human tetanus immune globulin (TIG)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

No Skin Test Required Before TIG Administration

Skin testing should NOT be performed before administering human tetanus immune globulin (TIG), as the FDA explicitly states that "skin tests should not be done" because intradermal injection of concentrated IgG solutions causes localized tissue inflammation that is often misinterpreted as an allergic reaction when it actually represents tissue irritation, not true allergy. 1

Why Skin Testing Is Contraindicated

  • The FDA drug label for human TIG clearly warns that skin testing can lead physicians to withhold needed human antitoxin from patients who are not actually allergic to the material 1

  • True allergic responses to human immunoglobulin given intramuscularly are extremely rare, making routine skin testing unnecessary and potentially harmful by causing treatment delays 1

  • The localized inflammation from intradermal concentrated IgG is a predictable tissue reaction, not an immunologic hypersensitivity, and should not guide clinical decision-making 1

Critical Distinction: Human vs. Equine Products

  • Skin testing recommendations apply only to equine (horse-derived) tetanus antitoxin, which is rarely used in developed countries due to higher rates of anaphylaxis and serum sickness 2

  • Modern purified human TIG products have eliminated the need for skin testing that was historically required for equine products 2

  • If equine rabies immune globulin must be used (typically only in resource-limited settings), a positive skin test is defined as a wheal >10 mm diameter with or without flare, or a wheal 5-10 mm with flare >20 mm, though even this test does not predict serum sickness 2

Proper TIG Administration Without Skin Testing

  • Administer TIG 250 units IM immediately when indicated (patients with <3 documented tetanus doses or unknown vaccination history presenting with any wound) 3, 1

  • Use separate syringes at different anatomical sites when giving both TIG and tetanus toxoid to prevent interference with immune response 3, 4

  • Inject preferably into the deltoid muscle of the upper arm or lateral thigh muscle; avoid the gluteal region due to sciatic nerve injury risk 1

  • Draw back on the syringe plunger before injection to ensure the needle is not in a blood vessel, as intravenous injection can cause precipitous blood pressure drops 1

Safety Considerations

  • Although systemic reactions to human immunoglobulin preparations are rare, epinephrine should be available for treatment of acute anaphylactic reactions 1

  • The combination of active (tetanus toxoid) and passive (TIG) immunization shows complete absence of interference when given simultaneously at separate sites 5

  • Human TIG is strongly preferred over equine antitoxin because it provides longer protection and causes fewer adverse reactions 3

References

Research

Value of skin testing for predicting reactions to equine rabies immune globulin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995

Guideline

Tetanus Toxoid Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Tetanus Vaccination for Nail Penetration Injury

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Active immunization against tetanus in man. II. Combined active and passive prophylaxis with human tetanus immune globulin.

Zeitschrift fur Immunitatsforschung, experimentelle und klinische Immunologie, 1976

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.